6Cella DF,Bonomi AE,Lloyd SR,Tulsky DS,Kaplan E,Bonomi P.Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument.Lung Cancer.1995; 12(3):199-220.
7Pfister DG,Johnson DH,Azzoli CG,Sause W,Smith TJ,Baker Jr S,Olak J,Stover D,Strawn JR,Turrisi AT,Somerfield MR.American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline.J Clin Oncol.2004; 22(2):330-353.
8Goldie JH,Coldman AJ.A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate.Cancer Treat Rep.1979; 63 (11-12):1727-1733.
9Brodowicz T,Krzakowski M,Zwitter M,Tzekova V,Ramlau R,Ghilezan N,Ciuleanu T,Cucevic B,Gyurkovits K,Ulsperger E,Jassem J,Grgic M,Saip P,Szilasi M,Wihschke C,Wagnerova M,Oskina N,Soldatenkova V,Zielinski C,Wenczl M; Central European Cooperative Oncology Group CECOG.Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer:A phase Ⅲ trial.Lung Cancer.2006; 52(2):155-163.
